The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

Martyna Szpakowska; Ann M. Decker; Max Meyrath; Christie B. Palmer; Bruce E. Blough; Ojas A. Namjoshi; Andy Chevigné

doi:10.1038/s41392-021-00548-w

The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

Martyna Szpakowska
, Ann M. Decker
, Max Meyrath
, Christie B. Palmer
, Bruce E. Blough
, Ojas A. Namjoshi
, Andy Chevigné^*

^*Corresponding author for this work

Immuno-Pharmacology and Interactomics

Research output: Contribution to journal › Letter › peer-review

21 Citations (Scopus)

Original language	English
Article number	209
Pages (from-to)	209
Journal	Signal Transduction and Targeted Therapy
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/s41392-021-00548-w
Publication status	Published - 2 Jun 2021

Access to Document

10.1038/s41392-021-00548-wLicence: CC BY

Cite this

@article{ccea6d50f8304efbaa0c36e4b453772f,

title = "The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7",

author = "Martyna Szpakowska and Decker, \{Ann M.\} and Max Meyrath and Palmer, \{Christie B.\} and Blough, \{Bruce E.\} and Namjoshi, \{Ojas A.\} and Andy Chevign{\'e}",

note = "Funding Information: This study was supported by the Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (Pathfinder “LIH383”, INTER/FWO “Nanokine” grant 15/ 10358798, INTER/FNRS grants 20/15084569, PoC “Megakine” 19/14209621 and PRIDE 11012546 “NextImmune” and 14254520 “I2TRON”), F.R.S.-FNRS-T{\'e}l{\'e}vie (grants 7.4593.19, 7.4529.19, and 7.8504.20) and by RTI International Internal Research and Development Funds (awarded to O.N.). M.M. and C.P. are Luxembourg National Research Fund PhD fellows (grants AFR-3004509 and AFR-14616593). C.P. is of part of the Marie Sk{\l}odowska-Curie Innovative Training Networks ONCORNET2.0 “ONCOgenic Receptor Network of Excellence and Training” (MSCA-ITN-2020-ETN). We wish to thank Manuel Counson for technical assistance in binding competition experiments.",

year = "2021",

month = jun,

day = "2",

doi = "10.1038/s41392-021-00548-w",

language = "English",

volume = "6",

pages = "209",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

AU - Szpakowska, Martyna

AU - Decker, Ann M.

AU - Meyrath, Max

AU - Palmer, Christie B.

AU - Blough, Bruce E.

AU - Namjoshi, Ojas A.

AU - Chevigné, Andy

N1 - Funding Information: This study was supported by the Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (Pathfinder “LIH383”, INTER/FWO “Nanokine” grant 15/ 10358798, INTER/FNRS grants 20/15084569, PoC “Megakine” 19/14209621 and PRIDE 11012546 “NextImmune” and 14254520 “I2TRON”), F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19, and 7.8504.20) and by RTI International Internal Research and Development Funds (awarded to O.N.). M.M. and C.P. are Luxembourg National Research Fund PhD fellows (grants AFR-3004509 and AFR-14616593). C.P. is of part of the Marie Skłodowska-Curie Innovative Training Networks ONCORNET2.0 “ONCOgenic Receptor Network of Excellence and Training” (MSCA-ITN-2020-ETN). We wish to thank Manuel Counson for technical assistance in binding competition experiments.

PY - 2021/6/2

Y1 - 2021/6/2

UR - https://www.scopus.com/pages/publications/85107397352

UR - https://www.ncbi.nlm.nih.gov/pubmed/34075018

U2 - 10.1038/s41392-021-00548-w

DO - 10.1038/s41392-021-00548-w

M3 - Letter

C2 - 34075018

AN - SCOPUS:85107397352

SN - 2095-9907

VL - 6

SP - 209

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 209

ER -

The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

Access to Document

Other files and links

Cite this